Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

589 ARTÍCULOS , VIENDO DEL 241 AL 255

Recent advance on pleiotropic cholinesterase inhibitors bearing amyloid modulation efficacy

Zhang H, Peng Y, Zhuo L, Wang Y, Zeng G, Wang S, Long L, Li X, Wang Z.

Eur J Med Chem. 2022 Nov 15;242:114695. doi: 10.1016/j.ejmech.2022.114695. Epub 2022 Aug 27.

Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer's Disease

Wu L, Xian X, Xu G, Tan Z, Dong F, Zhang M, Zhang F.

Mediators Inflamm. 2022 Aug 21;2022:7924199. doi: 10.1155/2022/7924199. eCollection 2022.

Ever-expanding landscape: Alzheimer's - new targets and new patents

Egunlusi AO, Joubert J.

Pharm Pat Anal. 2022 Sep;11(5):135-138. doi: 10.4155/ppa-2022-0031. Epub 2022 Sep 2.

Targeted Mitochondrial Epigenetics: A New Direction in Alzheimer's Disease Treatment

Song Y, Zhu XY, Zhang XM, Xiong H.

Int J Mol Sci. 2022 Aug 26;23(17):9703. doi: 10.3390/ijms23179703.

The Impairment of Blood-Brain Barrier in Alzheimer's Disease: Challenges and Opportunities with Stem Cells

López-Ornelas A, Jiménez A, Pérez-Sánchez G, Rodríguez-Pérez CE, Corzo-Cruz A, Velasco I, Estudillo E.

Int J Mol Sci. 2022 Sep 4;23(17):10136. doi: 10.3390/ijms231710136.

Combination Therapy for the Treatment of Alzheimer's Disease: Recent Progress and Future Prospects

Shirbhate E, Patel VK, Tiwari P, Kore R, Veerasamy R, Mishra A, Rajak H.

Curr Top Med Chem. 2022;22(22):1849-1867. doi: 10.2174/1568026622666220907114443.

Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease

Nolan JM, Power R, Howard AN, Bergin P, Roche W, Prado-Cabrero A, Pope G, Cooke J, Power T, Mulcahy R.

J Alzheimers Dis. 2022;90(1):233-249. doi: 10.3233/JAD-220556.

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial

Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, Gueorguieva I, Hauck PM, Brooks DA, Mintun MA, Sims JR.

JAMA Neurol. 2022 Oct 1;79(10):1015-1024. doi: 10.1001/jamaneurol.2022.2793.

BChE inhibitors from marine organisms - A review

Lins Alves LK, Cechinel Filho V, de Souza RLR, Furtado-Alle L.

Chem Biol Interact. 2022 Nov 1;367:110136. doi: 10.1016/j.cbi.2022.110136. Epub 2022 Sep 9.

Review of lipoic acid: From a clinical therapeutic agent to various emerging biomaterials

Lv SY, He S, Ling XL, Wang YQ, Huang C, Long JR, Wang JQ, Qin Y, Wei H, Yu CY.

Int J Pharm. 2022 Nov 5;627:122201. doi: 10.1016/j.ijpharm.2022.122201. Epub 2022 Sep 14.

Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil

Tariot PN, Braeckman R, Oh C.

J Alzheimers Dis. 2022;90(1):161-172. doi: 10.3233/JAD-220530.

Effects of Hypertension on Alzheimer's Disease and Related Disorders

Malone JE, Elkasaby MI, Lerner AJ.

Curr Hypertens Rep. 2022 Dec;24(12):615-625. doi: 10.1007/s11906-022-01221-5. Epub 2022 Sep 20.

Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration

Jiang Y, Alam JJ, Gomperts SN, Maruff P, Lemstra AW, Germann UA, Stavrides PH, Darji S, Malampati S, Peddy J, Bleiwas C, Pawlik M, Pensalfini A, Yang DS, Subbanna S, Basavarajappa BS, Smiley JF, Gardner A, Blackburn K, Chu HM, Prins ND, Teunissen CE, Harrison JE, Scheltens P, Nixon RA.

Nat Commun. 2022 Sep 21;13(1):5308. doi: 10.1038/s41467-022-32944-3.

Glial Cell-Mediated Neuroinflammation in Alzheimer's Disease

Al-Ghraiybah NF, Wang J, Alkhalifa AE, Roberts AB, Raj R, Yang E, Kaddoumi A.

Int J Mol Sci. 2022 Sep 12;23(18):10572. doi: 10.3390/ijms231810572.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias